Literature DB >> 20214609

Phage therapy in clinical practice: treatment of human infections.

Elizabeth Kutter1, Daniel De Vos, Guram Gvasalia, Zemphira Alavidze, Lasha Gogokhia, Sarah Kuhl, Stephen T Abedon.   

Abstract

Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the world's imagination--see, especially, Arrowsmith by Sinclair Lewis (1925)--and which today is the primary motivator of the field. Nonetheless, though the first human phage therapy took place in the 1920s, by the 1940s the field, was in steep decline despite early promise. The causes were at least three-fold: insufficient understanding among researchers of basic phage biology; over exuberance, which led, along with ignorance, to carelessness; and the advent of antibiotics, an easier to handle as well as highly powerful category of antibacterials. The decline in phage therapy was neither uniform nor complete, especially in the former Soviet Republic of Georgia, where phage therapy traditions and practice continue to this day. In this review we strive toward three goals: 1. To provide an overview of the potential of phage therapy as a means of treating or preventing human diseases; 2. To explore the phage therapy state of the art as currently practiced by physicians in various pockets of phage therapy activity around the world, including in terms of potential commercialization; and 3. To avert a recapitulation of phage therapy's early decline by outlining good practices in phage therapy practice, experimentation, and, ultimately, commercialization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214609     DOI: 10.2174/138920110790725401

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  197 in total

1.  P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections.

Authors:  Ragini Gupta; Yogendra Prasad
Journal:  Curr Microbiol       Date:  2011-04-27       Impact factor: 2.188

2.  The phage therapy paradigm: prêt-à-porter or sur-mesure?

Authors:  Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Maia Merabishvili; Nina Chanishvili; Mario Vaneechoutte; Martin Zizi; Geert Laire; Rob Lavigne; Isabelle Huys; Guy Van den Mooter; Angus Buckling; Laurent Debarbieux; Flavie Pouillot; Joana Azeredo; Elisabeth Kutter; Alain Dublanchet; Andrzej Górski; Revaz Adamia
Journal:  Pharm Res       Date:  2010-11-10       Impact factor: 4.200

3.  Identification and genomic analysis of a novel member of Microviridae, IME-16, through high-throughput sequencing.

Authors:  Peng Shu; Azeem Mehmood Butt; Zhiqiang Mi; Wei Wang; Xiaoping An; Guangqian Pei; Zhiyi Zhang; Yong Huang; Xianglilan Zhang; Taoxing Shi; Yigang Tong
Journal:  Virol Sin       Date:  2015-08       Impact factor: 4.327

4.  Genomic characterization of Salmonella bacteriophages isolated from India.

Authors:  Yogesh A Karpe; Gayatri D Kanade; Kunal D Pingale; Vidya A Arankalle; Kalyan Banerjee
Journal:  Virus Genes       Date:  2016-01-12       Impact factor: 2.332

5.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Molecular imaging of T4 phage in mammalian tissues and cells.

Authors:  Zuzanna Kaźmierczak; Agnieszka Piotrowicz; Barbara Owczarek; Katarzyna Hodyra; Paulina Miernikiewicz; Dorota Lecion; Marek Harhala; Andrzej Górski; Krystyna Dąbrowska
Journal:  Bacteriophage       Date:  2014-02-27

7.  Bi- and Multi-directional Gene Transfer in the Natural Populations of Polyvalent Bacteriophages, and Their Host Species Spectrum Representing Foodborne Versus Other Human and/or Animal Pathogens.

Authors:  Ekaterine Gabashvili; Saba Kobakhidze; Stylianos Koulouris; Tobin Robinson; Mamuka Kotetishvili
Journal:  Food Environ Virol       Date:  2021-01-23       Impact factor: 2.778

8.  Experimental phage therapy of burn wound infection: difficult first steps.

Authors:  Thomas Rose; Gilbert Verbeken; Daniel De Vos; Maya Merabishvili; Mario Vaneechoutte; Rob Lavigne; Serge Jennes; Martin Zizi; Jean-Paul Pirnay
Journal:  Int J Burns Trauma       Date:  2014-10-26

9.  Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections.

Authors:  Victor Krylov; Olga Shaburova; Elena Pleteneva; Sergey Krylov; Alla Kaplan; Maria Burkaltseva; Olga Polygach; Elena Chesnokova
Journal:  Virol Sin       Date:  2015-02-05       Impact factor: 4.327

10.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.